Breast cancer: NICE approves new drug combination treatmentBMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l4727 (Published 17 July 2019) Cite this as: BMJ 2019;366:l4727
- Elisabeth Mahase
- The BMJ
A new drug combination option for some patients with advanced breast cancer will now be available through the Cancer Drugs Fund, say new draft guidelines from the National Institute for Health and Care Excellence (NICE).1
The guidance has recommended ribociclib (Kisqali) with fulvestrant as an option for people with hormone receptor positive, human epidermal growth factor receptor 2 negative, locally advanced or metastatic breast cancer who have had previous endocrine therapy.
Ribociclib, a CDK4/6 …